Patents Examined by Maury Audet
  • Polypeptides, nucleic acids and uses thereof
    Patent number: 10689428
    Abstract: We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of: SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripotency of a stem cell.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 23, 2020
    Assignee: Agency For Science, Technology And Research
    Inventor: Bruno Reversade
  • Surface-immobilized antimicrobial peptoids
    Patent number: 10676509
    Abstract: Immobilizable antimicrobial compounds incorporating antimicrobial and/or antifouling components, as can be adhered to various device structures and components.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: June 9, 2020
    Assignee: Northwestern University
    Inventors: Phillip B. Messersmith, Annelise E. Barron, Andrea Statz, Nathaniel Chongslriwatana
  • Multitarget-directed bio-inorganic hybrid structure
    Patent number: 10669313
    Abstract: Provided herein is a multitarget-directed bio-inorganic hybrid structure. The hybrid structure is based on carbon nanotubes, and includes: carbon nanotubes; and two or more peptides bound to a surface of the carbon nanotubes and each independently interacting with different target molecules.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 2, 2020
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Yong Beom Lim, Woo Jin Jeong
  • Cystargolide compounds and uses thereof
    Patent number: 10662221
    Abstract: There is provided herein compounds of formula I, wherein R1 is H or linear or branched C1-C6 lower alkyl; R2 is H, linear or branched C1-C6 lower alkyl, or a proteinogenic amino acid side chain; R3 is H, linear or branched C1-C6 lower alkyl, or a proteinogenic amino acid side chain; R4 is —OH or —O—R5 wherein R5 is linear or branched C1-C6 lower alkyl; and each R6 is independently H or —CH3; or a pharmaceutically acceptable prodrug, salt, or ester thereof. Compositions containing said compounds, and uses thereof, are also provided.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: May 26, 2020
    Assignee: UNIVERSITY OF PRINCE EDWARD ISLAND
    Inventors: Krista Ann Gill, Fabrice Berrue, Russell Greig Kerr
  • Treating hyperammonemia, reducing plasma ammonia with TLR4 antagonists
    Patent number: 10639346
    Abstract: The present invention derives from the finding that increased levels of Toll like receptor 4 (TLR4) is associated with liver failure and renal dysfunction and/or brain dysfunction and that by decreasing TLR4 levels in vivo, the kidney and brain consequences of liver disease that are precipitated by superimposed infection or inflammation may be reduced. Accordingly, the invention provides TLR4 antagonists for use in a method of treating an individual suffering from liver disease presenting with renal or brain dysfunction.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: May 5, 2020
    Assignee: Yaqrit Limited
    Inventors: Rajiv Jalan, Naina Shah
  • Anti-endotoxin polypeptide
    Patent number: 10611799
    Abstract: An anti-endotoxin polypeptide is provided. The anti-endotoxin polypeptide having the formula (I) A1-L-C1, wherein A1 and C1 independently is a short peptide with ?-helix, L is AGP (Ala-Gly-Pro) or a peptide bond, and the hydrophobicity of the hydrophobic terminus in the anti-endotoxin polypeptide is between about 0.425 and 0.765. The anti-endotoxin polypeptide of the invention can neutralize the lipopolysaccharide and has the low hemolysis and high salt resistance, simultaneously. The present invention also provides a method for design an anti-endotoxin polypeptide, the anti-endotoxic activity is adjusted through increasing and/or decreasing hydrophobicity of the hydrophobic terminal end.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 7, 2020
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Jya-Wei Cheng, Hung-Lun Chu, Ya-Han Chih, Hui-Yuan Yu
  • Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
    Patent number: 10610595
    Abstract: Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 7, 2020
    Assignee: SANOFI
    Inventors: Oliver Bley, Petra Loos, Bernd Bidlingmaier, Walter Kamm, Harald Berchtold
  • Modular imaging agents containing amino acids and peptides
    Patent number: 10610608
    Abstract: Targeted molecular imaging agents (TMIAs) are derived from coupling together pre-formed amino acids with imaging agents attached to their side chains. These peptide-based imaging agents may synthesized from a single or multiple preformed amino acids containing multi-modal, multi-chelated metal, multi-dye imaging agents, or combinations of these, on the side chains of resultant peptides. These imaging amino acids or peptides may be conjugated directly, or activated, or attached to linkers to which targeting groups, such as peptides, proteins, antibodies, aptamers, or small molecule inhibitors, may be conjugated in the final steps of the synthesis to form a wide variety of TMIAs.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: April 7, 2020
    Assignee: Rochester Institute of Technology
    Inventors: Hans F. Schmitthenner, Stephanie Beach, Taylor Barrett, Chelsea Weidman
  • Formulations of hepalatide
    Patent number: 10603352
    Abstract: The present disclosure provides a drug formulation for hepalatide, comprising hepalatide and a buffer salt, and containing or not containing an osmotic regulator and/or an excipient.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 31, 2020
    Assignee: Shanghai HEP Pharmaceutical Co., Ltd.
    Inventor: Hongli Liu
  • Device and use thereof in cell experiments in vitro
    Patent number: 10597634
    Abstract: The invention provides a device and the use thereof in a cell experiment in vitro. This device has a polydopamine layer-carboxymethyl chitosan layer-peptide layer structure, which is capable of regulating behaviors of human pluripotent stem cells and is useful in cell culture or a cell experiment in vitro.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: March 24, 2020
    Assignee: Peking University School and Hospital of Stomatology
    Inventors: Shicheng Wei, Ping Zhou, Xiaohong Zhang, Yongliang Li, Mengke Wang
  • Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
    Patent number: 10576124
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: March 3, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Pharmaceutical composition for a sustained release of lanreotide
    Patent number: 10543249
    Abstract: A pharmaceutical composition for a sustained release of peptide therapeutics, in particular for a sustained release compatible with therapeutic treatments of at least two months. In an embodiment, the composition comprises lanreotide as an active agent, a hydrosoluble co-solvent, and water with the pH of the composition being from 4.0 to 7.5.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: January 28, 2020
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Ruth Bielsa Guivernau, Roland Cherif-Cheikh, Julie Fournes, Daniel Martinez Lorente, Anne Petit, Joël Richard
  • Inhibition of gliadin peptides
    Patent number: 10526372
    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: January 7, 2020
    Assignee: ALBA THERAPEUTICS CORPORATION
    Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
  • Peptides for prevention of HIV infection
    Patent number: 10512666
    Abstract: Two peptides that can selectively bind to SEVI and block the enhanced infectivity that results from the interaction of SEVI with HIV. The two peptides comprise the amino acid sequences FEEIVQEIEDFLENLV (SEQ. ID NO: 1) and GIGAVLEVLTTGLPALISWIEEEEQQ (SEQ. ID. NO: 2). The peptides may be administered topically, either alone or in combination with other prophylactics, agents, etc.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: December 24, 2019
    Assignee: SYRACUSE UNIVERSITY
    Inventor: Ivan V. Korendovych
  • Protein purification
    Patent number: 10501491
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: December 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Reagents and methods for inhibiting or disrupting biofilm
    Patent number: 10499655
    Abstract: The present disclosure provides an inhibitor for inhibiting or disrupting biofilm and use thereof. Specifically, the present disclosure an application of a PsIG protein and a coding sequence thereof in inhibiting or disrupting a biofilm of a microorganism. The present disclosure also provides a composition and a preparation containing the PsIG protein to inhibit or disrupt a biofilm of a microorganism. The experiment shows that PsIG can effectively inhibit or disrupt a biofilm of Pseudomonas species, suggesting the great potential of PsIG in clinical and environmental fields.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: December 10, 2019
    Assignee: INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES
    Inventors: Lvyan Ma, Shan Yu, Huijun Wu, Shiwei Wang, Di Wang
  • Low molecular polypeptide for preventing and treating inflammation and use thereof
    Patent number: 10501511
    Abstract: Disclosed are a low molecular polypeptide for preventing and treating inflammation, a preparation method and the use thereof and a pharmaceutical composition containing the polypeptide, wherein the polypeptide can penetrate the eye tissue barrier, can maintain a high concentration in neutral tears, aqueous humour and vitreous humour, and can be used to treat inflammation.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: December 10, 2019
    Assignee: SHANGHAI FIRST PEOPLE'S HOSPITAL
    Inventors: Xun Xu, Lili Wang, Yi Xu
  • Mutated immunoglobulin-binding polypeptides
    Patent number: 10501557
    Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: December 10, 2019
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav Rodrigo, Tomas Bjorkman, Mats Ander
  • Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same
    Patent number: 10494403
    Abstract: A cyclopeptide is disclosed, which is represented by the following formula (I) or (I?): wherein R1 and G? are defined in the specification. In addition, a pharmaceutical or cosmetic composition comprising the same and a method for preparing the same are also disclosed.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: December 3, 2019
    Assignee: CIPHORE BIOMED TECHNOLOGY LIMITED COMPANY
    Inventor: Po-Ruay Chen
  • Templates for controlling synthesis of nanoparticles into discrete assemblies
    Patent number: 10479817
    Abstract: An approach to synthesizing and assembling nanoparticles into discrete, size-tunable, pre-designed architectures is realized in a single synthetic/process step.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: November 19, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nathaniel L. Rosi, Chun-Long Chen